Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Matthew, Braithwaite"'
Autor:
Andrew, Trunk, Matthew, Braithwaite, Christopher, Nevala-Plagemann, Lisa, Pappas, Benjamin, Haaland, Ignacio, Garrido-Laguna
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:144-150
Background: BRAF mutations portend a poor prognosis in metastatic colorectal cancer (mCRC). Whether these patients may benefit from more aggressive frontline chemotherapy with a triplet regimen such as FOLFOXIRI remains unclear. We used real-world da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92580bab3732cdd58d1e3971bf11901a
https://doi.org/10.6004/jnccn.2021.7059
https://doi.org/10.6004/jnccn.2021.7059
Autor:
Brian Locke, Greg Sturgeon, Matthew Braithwaite, Caroline K. Milne, Marja Anton, Josephine Wright, Aaron Crosby
Publikováno v:
J Grad Med Educ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afef4d695fb1210ac04309fb6140f55c
https://pubmed.ncbi.nlm.nih.gov/32879675
https://pubmed.ncbi.nlm.nih.gov/32879675
Autor:
Ignacio Garrido-Laguna, Benjamin Haaland, Lisa Pappas, Christopher Nevala-Plagemann, Kelsey Baron, Matthew Braithwaite
Publikováno v:
Journal of Clinical Oncology. 38:4030-4030
4030 Background: BRAF mutations portend a poor prognosis in metastatic colorectal cancer (mCRC). Recent trials have hypothesized that using more aggressive triplet-based chemotherapy regimens such as FOLFOXIRI in the frontline setting may improve out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b0d8e9ee47e6aba5e9144aba02228ad
https://doi.org/10.1200/jco.2020.38.15_suppl.4030
https://doi.org/10.1200/jco.2020.38.15_suppl.4030
Autor:
A. Oliver Sartor, David D. Stenehjem, Andrew W. Hahn, Matthew Braithwaite, Michael B. Lilly, Elisa Ledet, Roberto Nussenzveig, Neeraj Agarwal, Benjamin L. Maughan
Publikováno v:
Journal of Clinical Oncology. 36:5048-5048
5048Background: Two androgen axis inhibitors, enza and AA plus prednisone, are approved for the treatment of advanced prostate cancer (aPC). Although initial responses are common with these agents,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2239c8e279856edc0d394c8da5e9d881
https://doi.org/10.1200/jco.2018.36.15_suppl.5048
https://doi.org/10.1200/jco.2018.36.15_suppl.5048
Autor:
Joseph E. Italiano, Jordan M Anderson-Daniels, Mark K. Larson, Karin M. Hoffmeister, Jonathan N. Thon, John H. Hartwig, Matthew Braithwaite
Publikováno v:
Blood. 114:4590-4590
Abstract 4590 Megakaryocytes generate platelets by remodeling their cytoplasm into long proplatelet extensions from which platelets release. While the mechanics of proplatelet elongation have been studied, the terminal steps of platelet production re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92ca0bdede70eb743f31dda60e8003a3
https://doi.org/10.1182/blood.v114.22.4590.4590
https://doi.org/10.1182/blood.v114.22.4590.4590